

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

---

Date of Report (Date of earliest event reported): October 19, 2015

**BioSig Technologies, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction  
of incorporation)

**000-55473**

(Commission File Number)

**26-4333375**

(IRS Employer  
Identification No.)

**8441 Wayzata Blvd., Suite 240**

**Minneapolis, Minnesota**

(Address of principal executive offices)

**55426**

(Zip Code)

Registrant's telephone number, including area code: **(763) 999-7330**

---

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On October 19, 2015, Asher Holzer submitted his resignation as a member of the Board, subject to acceptance by the Board, which occurred on October 19, 2015 (the “*Effective Date*”).

On the Effective Date, the Board appointed Donald E. Foley as a member of the Board, effective as of the Effective Date, to serve for a term expiring at the Company’s 2016 annual meeting of stockholders or until his successor is duly elected and qualified or his earlier death, resignation or removal, and as a member of the Company’s Nominating and Corporate Governance Committee, until his successor shall be duly appointed and qualified or his earlier death, resignation or removal.

Mr. Foley, age 62, brings extensive financial, economic, capital markets and executive leadership expertise to the Company gained through his successful career on Wall Street and the Fortune 500. Mr. Foley was chairman of the board and chief executive officer of Wilmington Trust Corporation from 2010-2011. Prior to Wilmington Trust Corporation, Mr. Foley was senior vice president, treasurer and director of tax for ITT Corporation, a supplier of advanced technology products and services. Mr. Foley currently serves on the board of directors of AXA Equitable EQAT Mutual Funds and is an advisory board member of M&T Corporation Trust and Investment Committee. In addition, Mr. Foley served on the boards of directors of M&T Corporation from 2011-2012 and of Wilmington Trust Company and Wilmington Trust Corporation from 2007-2011. Mr. Foley holds an M.B.A. from New York University and a B.A. from Union College. He is also a member of the board of trustees of Burke Rehabilitation Hospital and Burke Medical Research Institute, as well as the W. Burke Foundation.

In connection with his appointment to the Board, effective the later to occur of (i) the date Mr. Foley executes his board service offer letter and (ii) the Effective Date (such date being the “*Date of Grant*”), the Company granted Mr. Foley a stock option to purchase 250,000 shares of the Company’s common stock, par value \$0.001 (the “*Common Stock*”) with (i) an exercise price equal to the fair market value of a share of Common Stock on the Date of Grant, (ii) a term of ten years, and (iii) one-twelfth of the stock options vesting on each three-month anniversary of the Date of Grant until the stock options shall have fully vested, and in connection with his appointment to the Nominating and Corporate Governance Committee, effective the Date of Grant, the Company granted Mr. Foley a stock option to purchase an additional 25,000 shares of Common Stock with (a) an exercise price equal to the fair market value of a share of Common Stock on the Date of Grant, (b) a term of ten years, and (c) one-twelfth of the stock options vesting on the same day of the month as the Date of Grant that occurs in each of the subsequent twelve months, in each case provided Mr. Foley is providing services to the Company through the applicable vesting dates (the “*Foley Grant*”). The Foley Grant is subject to the terms and conditions of the BioSig Technologies, Inc. 2012 Equity Incentive Plan and the Company’s standard form of stock option agreement.

**Item 8.01 Other Events.**

On October 22, 2015, the Company issued a press release announcing the appointment of Mr. Foley to the Board. A copy of the press release is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

<u>Exhibit Number</u>	<u>Description</u>
99.1	<a href="#">Press release dated October 22, 2015</a>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**BIO SIG TECHNOLOGIES, INC.**

Date: October 23, 2015

By: /s/ Kenneth Londoner

\_\_\_\_\_  
Kenneth Londoner  
Executive Chairman

---





October 22, 2015

## **BioSig Technologies, Inc. Appoints Donald E. Foley to its Board of Directors**

### ***Accomplished Finance and Institutional Money Management CEO to Join Independent Board and Add Significant Capital Markets, Strategy, and Policy Experience***

**Minneapolis, MN / October 22, 2015** / BioSig Technologies, Inc. (OTCQB: BSGM) today announced that it has appointed Donald E. Foley to the Board of Directors, effective immediately. Mr. Foley takes the seat of Dr. Asher Holzer, who has agreed to vacate his Board position and take the role of Chief Scientific Officer of the Company. Dr. Holzer has proudly served on the BioSig Board since 2010 and has brought significant value to the shareholders and will continue to in his new position.

Mr. Foley brings extensive financial, economic, capital markets, executive leadership expertise to the Company gained through his successful career on Wall Street and the Fortune 500.

Mr. Foley was elected chief executive officer and chairman of Wilmington Trust in June and July 2010. He joined the Board of Directors in July 2006.

Prior to becoming CEO of Wilmington Trust, Mr. Foley served as senior vice president, treasurer and director of the ITT Corporation, a supplier of advanced technology products and services. He was responsible for ITT's capital and financing activities, as well as its pension and defined contribution investments. In addition, he was a member of the company's Executive Council, chairman of ITT Industries of Canada, and served on the boards of several other direct investments and international subsidiaries.

Previously, Mr. Foley was assistant treasurer for International Paper Company and held a progression of capital market, treasury, and tax-related assignments at Mobil Corporation. He began his career at General Electric.

In addition to his experience in leading global companies, Mr. Foley has also been both a member and chairman of the Board of Trustees of Burke Rehabilitation Hospital in Westchester County, New York since 2005. Through his service to the healthcare sector, Mr. Foley has developed an appreciation for health care technology and the challenges and opportunities related to hospital administration.

Kenneth L. Londoner, executive chairman and co-founder of BioSig Technologies, stated, "We are excited to welcome Donald to our Board. Donald further complements and adds to the depth and strength of our independent Board. We look forward to learning from him and know our shareholders will benefit from his relationships and significant experience."

Mr. Foley stated, "BioSig Technologies has one of the strongest Boards I have seen for a company of its size. The company strongly believes in creating shareholder value, a philosophy I have followed my entire career. I am enthusiastic to bring my skills and relationships to complement my Board colleagues so we can establish BioSig as a market innovator and ultimately, a leader in the EP technology marketplace."

---

## **About BioSig Technologies**

BioSig Technologies is a medical device company that is developing a proprietary technology platform designed to improve the \$3 billion electrophysiology (EP) marketplace(1) ([www.biosigtech.com](http://www.biosigtech.com)). Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP System.

PURE EP System is a surface electrocardiogram and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing clarity of data which may be used to guide the EPs in identifying ablation targets - areas of tissue to treat that otherwise create a heart rhythm disturbance (arrhythmia).

Analysts forecast the global market for EP devices will grow at a 12.1 percent compound annual growth rate, from \$2.5 billion in 2012 to \$5.5 billion by 2019(1) - making it one of the fastest growing medical device segments. Just in the US, the number of Atrial Fibrillation (AF) and Ventricular Tachycardia (VT) arrhythmia ablations is forecast to grow at 10.5 percent from 2012 to 2017(2).

BioSig intends to seek FDA 510(k) clearance for the PURE EP System. The Company has achieved proof of concept validation through UCLA labs, and has performed preclinical studies at the Mayo Clinic in Minnesota. The Company is collaborating with several of the nation's most prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute, UCLA Cardiac Arrhythmia Center, and Mayo Clinic.

(1) Electrophysiology Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

(2) HRI 2013 "Global Opportunities in Medical Devices & Diagnostics" report; triangulation of multiple sources; \*AF includes left atrial tachycardia, left WPW, left atrial flutter.

## **Investor Relations**

Brian McLaughlin  
BioSig Technologies, Inc.  
[bmclaughlin@biosigtech.com](mailto:bmclaughlin@biosigtech.com)  
917-370-9817